Terumo acquires Medeon’s large bore vascular closure system for $20M

A stethoscope and paper money.
Taiwanese devicemaker Medeon sells its large bore vascular closure system to Terumo for $20 million. (iStock)

Medeon Biodesign, a Taiwanese maker of minimally invasive surgical devices, sold its large bore vascular closure system to Terumo for $20 million.

The XPro System is an automated suture-mediated closure device that simultaneously delivers two pairs of sutures during percutaneous large bore procedures, including transcatheter aortic valve replacement, endovascular aneurysm repair, thoracic endovascular aneurysm repair and percutaneous balloon aortic valvuloplasty procedures.

Under terms of the agreement, Tokyo-based Terumo will pay an upfront payment of $20 million and additional payments when certain milestones are met. The two companies will continue to collaborate on future regulatory developments of the device.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

"Access site complications in large bore procedures remain a significant concern among practicing clinicians,” Yue-Teh Jang, Ph.D., chairman and CEO of Medeon, said in a statement. “Leveraging the advantages of the security of suture-mediated closure and built-in safety mechanisms, the closure system provides a better solution for the large bore procedures with excellent outcomes and rapid hemostasis.”

The XPro system has successfully undergone a CE Marking clinical study in New Zealand, Australia and Taiwan. In those studies, the device achieved immediate or rapid hemostasis at the puncture sites, resulting in improved outcomes and earlier discharge from hospitals, the company said.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

Five years after Congress passed a law to reduce unnecessary MRIs and CT scans, federal officials have yet to implement it.